Thursday, August 17, 2017 11:01:17 AM
I happened to be reviewing the August 8 press release this morning with their second quarter results. Their position is laid out pretty clearly, financial and otherwise.
For financials, if I read this correctly, 2nd quarter R&D and Net & Comprehensive loss for the quarter add up to about $4.5M (compared to Q2 2016 total of $15.5M). They had $6.8M cash and equivalent on hand as of June 30, then closed the offering for over $5M and converted Longtai for another $2M. That's just about $14M total. If their burn rate remains fairly steady, they are funded halfway through Q1 2018.
For the "otherwise", Mr. McNally mentioned six non-financial achievements completed in Q2, the anticipated Q3 signing of the two remaining training centers for feasibility and validation studies, the initiation of those studies, and anticipated live animal studies beginning in Q4.
They said what they were doing and they are doing what they said. Really, little or no further clarification from them is warranted in that regard.
Honestly, I think part of the strength of this message board and its contributors is that we dig for details, we analyze them and sometimes over-analyze them, and for the most part we have a solid understanding of the company, the technology, and the personnel; certainly to a greater extent than most casual investors know the organizations they are invested in. This in-depth knowledge that we DO have causes us to raise further questions which equate to minutia of their daily operations. We know in general terms they are going to sign with two more training centers. Curiosity is driving to question more about when, and who, and what unique offerings each of them might bring to enhance our technology and its acceptance in the marketplace. We know too much and it makes us a bit too eager for more information. We are by no means under-informed; we are instead over-curious. In some ways rightfully so; most of us have supported the company through thick and thin so we find the current situation frustrating. But in reality, the flow of information is not unreasonable for the situation, and we aren't in the dark about anything that can be know or can reasonably be announced.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM